| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.15 | 0.4 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.046 | 0.4 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.046 | 0.4 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.14 | 0.4 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |